Table 3 Pharmacokinetic study design, characteristics and immediate post dose (IPD) BAL Ig recovery. For the NHP study, isotype measured by LC-MS is indicated into brackets
From: Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates
Species | Product | Overall Estimated Delivered Dose Level (mg/kg/day) | Highest IPD BAL recovery (μg) |
|---|---|---|---|
Rat | Vehicle | N/A | N/A |
IgG 5% | 31.7 | 4.2 | |
IgA 5% | 32.66 | 2.4 | |
IgAM 5% | 38.54 | 10.7 | |
NHP | Vehicle | N/A | N/A |
IgG 5% | 29.6 | 4368.4 (IgG1) | |
IgA 5% | 25.8 | 2454.6 (IgA1) | |
IgAM 5% | 25.6 | 4130.1 (IgA1) | |
1723.9 (IgM) |